Biardi and Krisans reported that MPD was mainly located in peroxisomes, since its activity was the same in extracts prepared from intact cells and selectively permeabilized cells that lacked cytosolic enzymes. 8) We previously reported that MPD was predominantly located in the cytosol and a small amount was present in peroxisomes. 11, 12) Years ago data have also shown that the activities of some enzymes, including MVK and FPPase, are significantly reduced in liver tissue obtained from patients with peroxisomedeficient diseases (Zellweger syndrome and neonatal adrenoleukodystrophy), thus indicating a peroxisomal localization of these enzymes. 10) Hogenboom et al. reported that the activities and protein levels of selected enzymes involved in cholesterol biosynthesis were at least as high in the peroxisome-deficient Zellweger mice as in control mice, indicating that mislocalization of enzymes to the cytosol does not lead to decreased activity or degradation of these enzymes. 13) They also reported that the previously reported deficiencies of MVK and PMVK activity in livers from human Zellweger patients reflect the bad condition of the livers, rather than mislocalization to the cytosol. 13) From these data, the relationship between peroxisome proliferation and the enzyme involved in cholesterol biosynthesis remains unclear.
In this study, we examined the change in the protein level of MPD in the crude extract, the cytosol and the peroxisomeenriched fraction of the livers of rats administered peroxisome proliferative drugs, to establish whether the expression of MPD depends on the peroxisome proliferation.
MATERIALS AND METHODS

Materials
Clofibrate was generously provided by Yamanouchi Pharmaceutical Co. (Tokyo). Dehydroisoandrosterone (DHEA) was purchased from Sigma. Rabbit anti-catalase antibody was purchased from Polysciences, Inc. All other chemicals were of reagent grade and purchased from commercial sources.
Animals Male Wistar Kyoto rats (10 weeks old, 280 g) were housed in a light-controlled room (light phase, 6:00-18:00). They were fed a powdered chow with or without 0.5% DHEA or 0.5% clofibrate as indicated in the figure legends. The rats were fed an average of 10 g a day.
Preparation of MPD Antibody MPD was purified from rat liver and polyclonal antiserum raised against the 45-kDa MPD as described by Michihara et al., 14) and purification of MPD antibody was carried out as described by Michihara et al.
11)
Preparation of Crude Extract Livers of rats fed normal chow or chow containing DHEA or clofibrate were homogenized in 3 volumes of buffer H (0.1 M phosphate buffer (pH 7.0), 1 mM EDTA, 10 mM 2-mercaptoethanol, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM leupeptin, 0.1 mM pepstatin A, 0.1 mM antipain, and 0.1 mM chymostatin) containing 1% Triton X-100. The homogenate was centrifuged at 106000ϫg for 1 h to obtain a crude extract.
Cell Fractionation Preparation of the cytosol and the peroxisome-enriched fraction was carried out according to Michihara et al. 12) Livers (8 g) of rats fed normal chow or chow supplemented with DHEA or clofibrate were washed with 0.1 M sodium phosphate (pH 7.0) containing 10 mM mercaptoethanol and 1 mM EDTA, and then homogenized with 3 volumes of ice-cold buffer H using a Polytron motordriven homogenizer. The homogenate was centrifuged at 1000ϫg for 10 min. The supernatant was saved, and then the pellet was resuspended, homogenized and centrifuged again at 1000ϫg for 10 min. The two supernatants were then combined and centrifuged at 7000ϫg for 6 min, and the supernatant was centrifuged at 20000ϫg for 20 min.
(i) The supernatant contained cytosol and microsomes. The pellet contained the peroxisome-enriched fraction.
The supernatant of (i) was centrifuged at 105000ϫg for 1 h and supernatant contained the cytosol fraction. The pellet of (ii) was dissolved in buffer H.
Immunoblot Procedures Western blot analysis was carried out using the ECL detection system. The Western blotting detection kit (Amersham, Bucks, U.K.) was used according to the manufacturer's instructions. The crude extract, cytosol and peroxisome-enriched fraction were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blot analysis using anticatalase antibody or anti-MPD antiserum. The results of immunoblot analysis of catalase and MPD using crude extract of the livers of rats fed normal chow are shown in Fig. 1 to demonstrate the specificity of the antibodies for catalase and MPD, respectively. Signal intensities were measured with a Shimadzu Chromatoscanner S-910 (Shimadzu, Tokyo), and an arbitrary value was assigned for 1 mg of crude extract in the liver.
Protein Determination Protein amounts were determined by the method of Lowry et al. 15) using bovine serum albumin as the standard.
RESULTS AND DISCUSSION
Increase of Peroxisomes by Peroxisome Proliferative Drugs
In general, DHEA and clofibrate are known to be peroxisome proliferative drugs and to cause increases in liver weight and catalase levels. Therefore, liver weight and the amount of catalase were measured as markers of peroxisome proliferation. The liver weight was increased 2.5-fold by administration of DHEA or clofibrate for 15 d, as compared with the corresponding value in rats fed normal chow for 15 d (Fig. 2) .
The results of immunoblot analysis performed with anticatalase antibody using the livers of rats fed peroxisome proliferative drugs or normal chow are shown in Fig. 3A . The amount of catalase was increased 3-fold by DHEA and 5-fold by clofibrate administration for 15 d, as compared with the corresponding values in rats fed normal chow for 15 d. These data indicate that peroxisomes were significantly increased by administration of peroxisome proliferative drugs for 15 d.
Relationship between the Proliferation of Peroxisomes and the Expression of MPD To establish whether the expression of MPD depended on the proliferation of peroxisomes, we examined the increase of MPD in crude liver extracts after administration of peroxisome proliferative drugs. There was no difference of the amount of MPD in crude extracts from rats administered clofibrate for 15 d and those fed normal chow for the same period (Fig. 3B) . The level of MPD in the crude extract was decreased 65% by administration of DHEA for 15 d, as compared with the level in rats fed normal chow for the same period (Fig. 3B) . These results indicate that the total amount of MPD was not increased by peroxisome proliferative drugs.
We previously reported that MPD was predominantly located in the cytosol and that a small amount is present in peroxisomes.
12) Therefore, we examined whether changes in the MPD levels in the cytosol and peroxisomes were induced by peroxisome proliferative drugs, in order to establish whether the amount of MPD in peroxisomes was increased. There was no difference in MPD amount in the cytosol or peroxisome-enriched fraction of rats treated with clofibrate for 15 d and those fed normal chow for the same period (Fig. 4) . Also, the levels of MPD in the cytosol and peroxisome-enriched fraction were decreased 65% and 50%, respectively, by DHEA administration for 15 d as compared with levels in rats fed normal chow for the same period (Fig. 4) . These results indicate that no increase of MPD in the cytosol or peroxisomes resulted despite the proliferation of peroxisomes. Peroxisome proliferative drugs such as clofibrate or DHEA have been shown to activate peroxisome proliferator-activated receptor alpha (PPARa), a member of the steroid nuclear receptor superfamily. 16) Hogenboom et al. reported that the activities and protein levels of MPD were at least as high in peroxisome-deficient Zellweger mice as in control mice. 13) Based on these facts, we consider that the expression of MPD is independent of the proliferation or deficiency of peroxisomes and may be maintained by a specific regulatory mechanism different from the regulation of expression by PPARa. In this study, the level of MPD was decreased by DHEA administration. It is known that enzymes involved in cholesterol biosynthesis in the livers of rats fed cholesterol is decreased by feedback control. Since DHEA is a metabolite of cholesterol, the decrease of MPD induced by DHEA may be caused by the same mechanism as feedback control by cholesterol. Further studies will be necessary to identify the mechanism regulating the level of MPD in the liver. 
